2020 PNS Virtual Event
27 JUNE – 30 JUNE, 2020

Program
Sunday 28 June 2020

7.00 PDT | 8.00 MDT | 9.00 CDT | 10.00 EDT | 15.00 BST | 16.00 CEST | 23.00 JST | 24.00 AEST

10.00-10.10 EDT
**Presidential Welcome, Announcement of Alan J Gebhart Prize, Recognition of new Fellows of the Academy of Medical Sciences (UK), Prof. James Lupski, Estelle Benson, Dr. Chris Gibbons, & Introduction of Keynote**

Pieter van Doorn, MD, PhD, President, *Erasmus MC University Medical Center, Rotterdam, The Netherlands*

10.10-10.40 EDT
**COVID-19 And the Nervous System: What we Know (and Don’t Know)**

James Sejvar, MD, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA

Chair: Pieter van Doorn, MD, PhD, *Erasmus MC University Medical Center, Rotterdam, The Netherlands*

10.40-12.10 EDT
**Clinical Trials Presentations**

Chairs: Mary Reilly, MD, FRCP, FRCPI, Institute of Neurology, London, UK; David Cornblath, MD, *The Johns Hopkins University, Baltimore, MD, USA*

10.40 EDT
**Correlation Between Neurofilament Light Chain and Patient Outcome in Guillain-Barré Syndrome: ANX005 Phase 1b Results**

Sanjay Keswani, MBBS, FRCP, Annexon Biosciences, San Francisco, CA, USA

10.55 EDT
**Preceding Infections in Guillain-Barré Syndrome: Results from the IGOS-1000 Cohort**

Sonja Leonhard, MD, *Erasmus University Medical Center, Rotterdam, The Netherlands*
# Program
Sunday 28 June 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.10</td>
<td>Pharmacokinetics of IVIg and Outcome in the Second IVIg Dose in Guillain-Barré Syndrome (SID-GBS) Trial Data: A Validation Study</td>
<td>Christa Walgaard, MD, Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands</td>
</tr>
<tr>
<td>11.25</td>
<td>Effects of Progressive Resistance Training in Patients with Type 2 Diabetic Polyneuropathy: A Randomized Single-blinded Controlled Trial</td>
<td>Karolina Khan, MD, PhD, Aarhus University, Aarhus, Denmark</td>
</tr>
<tr>
<td>11.40</td>
<td>Efficacy and Safety of 3 Different Dosages of IVIG (NewGam) in Patients with CIDP (ProCID Study)</td>
<td>David Cornblath, MD, The Johns Hopkins University, Baltimore, MD, USA</td>
</tr>
<tr>
<td>11.55</td>
<td>Escalation Treatment with Cyclophosphamide, Rituximab and Bortezomib in CIDP: Real-life Retrospective Analysis in 201 Patients</td>
<td>Jeremias Motte, MD, Ruhr-University Bochum, Bochum, Germany</td>
</tr>
<tr>
<td>12.10-12.30</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>
| 12.30-14.00 | Platform Presentations  
**Chairs:** Charlotte Sumner, MD, Johns Hopkins Medicine, Baltimore, MD, USA; Luis Querol, MD, PhD, Hospital de Sant Pau, Barcelona, Spain | |
| 12.30  | MTORC1 and 2 Signaling: Double the Trouble in Diabetic Neuropathy | Stephanie Eid, PhD, University of Michigan, Ann Arbor, MI, USA |
| 12.45  | Characterization of a Late Onset CMT1B Mouse Model: The Role of P0 in Schwann Cell-Axon Relationship | Ghjuvan Shackleford, PhD, San Raffaele Hospital Scientific Institute, Milano, Italy |
| 13.00  | Serum Neurofilament Light Chain Predicts Prognosis in Patients with Guillain-Barré Syndrome | Lorena Martín-Aguilar, MD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain |
| 13.15  | Biallelic Mutations in SORD are a Common Cause of Potentially Treatable Genetic Neuropathy | Andrea Cortese, MD, PhD, UCL Institute of Neurology, London, UK |
| 13.30  | New Insights into the Active Transport of Paclitaxel into the Sensory Neuron | Ines Muke, PhD, University Hospital Cologne, Cologne, Germany |
| 13.45  | The Integrated Stress Response Contributes to Disease in tRNA Synthetase-Associated Neuropathies | Robert Burgess, PhD, The Jackson Laboratory, Bar Harbor, ME, USA |
| 14.00-14.10 | Thank you, Farewell  
Pieter van Doorn, MD, PhD, Erasmus MC University Medical Center, Rotterdam, The Netherlands |
INFLAMMATORY NEUROPATHY CONSORTIUM (INC)

9.55-10.00 EDT | Welcome & Introduction
Peter Van den Bergh, MD, PhD, INC Chair, University Hospitals St-Luc, Brussels, Belgium

10.00-10.25 EDT | Novel Opportunities for Body Fluid Biomarker Development for Neurological Diseases
Charlotte Teunissen, PhD, Neurochemistry Lab, Amsterdam University Medical Centers, Amsterdam, The Netherlands
Chair: Robert Hadden, BM, BCh, FRCP, PhD, King’s College Hospital, London, UK

10.25-11.15 EDT | Oral Poster Presenters
Chair: Ruth Huizinga, PhD, Erasmus MC, Rotterdam, The Netherlands

10.25 EDT | Development of an Anti-GM1 Antibody-Specific Therapy for Guillain-Barré Syndrome and Multifocal Motor Neuropathy
Butrint Aliu, MSc, University of Basel, Basel, Switzerland
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.35 EDT</td>
<td><strong>Association of Serum Neurofilament Light Chain Levels with Clinicopathology and NF155 Autoantibodies in Patients with CIDP</strong>&lt;br&gt;Yuki Fukami, MD, Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan</td>
</tr>
<tr>
<td>10.45 EDT</td>
<td><strong>Blockade of Colony Stimulating Factor 1 Receptor Improves Inflammatory Nerve Injury</strong>&lt;br&gt;Tong Gao, PhD, University of Texas Health Science Center, Houston, TX, USA</td>
</tr>
<tr>
<td>10.55 EDT</td>
<td><strong>Cerebrospinal Fluid Protein Level and Cell Count in Diagnosis and Prognosis of Guillain-Barré Syndrome</strong>&lt;br&gt;Helle Al-Hakem, BSc, Aarhus University Hospital, Aarhus, Denmark</td>
</tr>
<tr>
<td>11.05 EDT</td>
<td><strong>Anti-Paranodal Autoantibodies in a Large GBS and Acute-onset CIDP Cohort with IgG Subclass Switch from Acute to Chronic Stage in One Patient</strong>&lt;br&gt;Luise Appeltshauser, MD, Department of Neurology, University Hospital of Würzburg, Würzburg, Germany</td>
</tr>
<tr>
<td>11.15-11.40 EDT</td>
<td><strong>Update on the Nonsystemic Vasculitic Neuropathies</strong>&lt;br&gt;Michael Collins, MD, Medical College of Wisconsin, Milwaukee, WI, USA&lt;br&gt;<em>Chair</em>: Robert Hadden, BM, BCh, FRCP, PhD, King’s College Hospital, London, UK</td>
</tr>
<tr>
<td>11.40-12.00 EDT</td>
<td><strong>INC Project Updates</strong>&lt;br&gt;<em>Chair</em>: Jeffrey Allen, MD, University of Minnesota, Minneapolis, MN, USA</td>
</tr>
<tr>
<td>11.40 EDT</td>
<td><strong>International GBS Outcome Study (IGOS)</strong>&lt;br&gt;Bart Jacobs, MD, PhD, Erasmus MC University Medical Center, Rotterdam, The Netherlands</td>
</tr>
<tr>
<td>11.45 EDT</td>
<td><strong>INCbase</strong>&lt;br&gt;Filip Eftimov, MD, PhD, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>11.50 EDT</td>
<td><strong>Italian Multicenter Database on Multifocal Motor Neuropathy (IDAM)</strong>&lt;br&gt;Eduardo Nobile-Orazio, MD, PhD, Milan University, Milan, Italy</td>
</tr>
<tr>
<td>11.55 EDT</td>
<td><strong>Building a Prospective Cohort of Patients with Idiopathic or Inflammatory Sensory Neuropathy</strong>&lt;br&gt;Jean-Christophe Antoine, MD, Chu Hospital de Bellevue, Saint-Étienne, France</td>
</tr>
<tr>
<td>12.00-12.05 EDT</td>
<td><strong>Closing Remarks</strong>&lt;br&gt;Peter Van den Bergh, MD, PhD, INC Chair, University Hospitals St-Luc, Brussels, Belgium</td>
</tr>
</tbody>
</table>
14.30 – 16.45 EDT

TOXIC NEUROPATHY CONSORTIUM (TNC)

14.30-14.35 EDT Welcome & Overview of TNC Content
Guido Cavaletti, MD, TNC Chair, University of Milano-Bicocca, Monza (I), Milan, Italy

14.35-15.05 EDT Toxic Neuropathies
Wolfgang Grisold, MD, PhD, FAAN, Ludwig Boltzmann Institute for Experimental und Clinical Traumatology, Vienna, Austria
Chair: Ellen Smith, PhD, APRN, AOCN®, FAAN, University of Michigan School of Nursing, Ann Arbor, MI, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.05-15.35 EDT</td>
<td>Pathogenic Role of Tubulin Post Translational Modifications in Axon Degeneration</td>
<td>Francesca Bartolini, PhD, Columbia University, New York, NY, USA</td>
<td>Chair: Ahmet Hoke, MD, PhD, Johns Hopkins University, Baltimore, MD, USA</td>
</tr>
<tr>
<td>15.35-15.50 EDT</td>
<td>Toxic Neuropathy Consortium Activities Update</td>
<td>Andreas Argyriou, PhD, Saint Andrew’s General Hospital, Patras, Greece</td>
<td></td>
</tr>
<tr>
<td>15.50-16.40 EDT</td>
<td>Abstract Presentations</td>
<td>Chairs: Sandra Rieger, PhD, University of Miami, Coral Gables, FL, USA; Susanna Park, PhD, University of Sydney, Sydney, Australia</td>
<td></td>
</tr>
<tr>
<td>15.50 EDT</td>
<td>Molsidomine Provides Neuroprotection Against Vincristine-induced Peripheral Neuropathy Through Soluble Guanylyl Cyclase Activation</td>
<td>Francesco Lotti, PhD, Columbia University Medical Center, New York, NY, USA</td>
<td></td>
</tr>
<tr>
<td>16.00 EDT</td>
<td>Usefulness of the Nerve Conduction Studies for Grading the Severity of Chemotherapy-Induced Peripheral Neurotoxicity</td>
<td>Roser Velasco, PhD, MD, University Hospital of Bellvitge, Barcelona, Spain</td>
<td></td>
</tr>
<tr>
<td>16.10 EDT</td>
<td>Chemotherapy-induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-term Quality of Life</td>
<td>Eva Battaglini, PhD, University of New South Wales, Sydney, Australia</td>
<td></td>
</tr>
<tr>
<td>16.20 EDT</td>
<td>Responsiveness and Minimal Clinical Important Difference (MCID) of the Total Neuropathy Score Clinical and Nurse Versions in CIPN</td>
<td>Paola Alberti, MD, PhD, University of Milano-Bicocca, Monza, Italy</td>
<td></td>
</tr>
<tr>
<td>16.30 EDT</td>
<td>Fibrates, Peroxisome Proliferator-activated Receptor – Agonists, for the Treatment of Paclitaxel-Induced Peripheral Neuropathy</td>
<td>Martial Caillaud, PhD, Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA</td>
<td></td>
</tr>
<tr>
<td>16.40-16.45 EDT</td>
<td>Thank you, Farewell</td>
<td>Guido Cavaletti, MD, TNC Chair, University of Milano-Bicocca, Monza (I), Milan, Italy</td>
<td></td>
</tr>
</tbody>
</table>
10.00-10.05 EDT
Welcome, Overview of CMTR, James Lupski CMTR Lifetime Achievement Award
Michael Shy, MD, CMTR Chair, University of Iowa, Carver College of Medicine, Iowa City, IA, USA

10.05-10.35 EDT
Research and Clinical Exome Sequencing (cES) in the Study of Neurodevelopmental and Neurodegenerative Disease
James R Lupski, MD, PhD, DSc (hon), Baylor College of Medicine, Houston, TX, USA
Chairs: Michael Shy, MD, University of Iowa, Carver College of Medicine, Iowa City, IA, USA; Stephan Zuchner, MD, PhD, University of Miami Miller School of Medicine, Miami, FL, USA
10.35-11.05 EDT  **Exploration of Giant Axonal Neuropathy Unveils Common Pathological Mechanisms amongst CMT Diseases: The Obvious and the Unexpected**
Pascale Bomont, PhD, INM-INSERM, University of Montpellier, Montpellier, France
*Chairs: Vincent Timmerman, MSc, PhD, University of Antwerp, Antwerp, Belgium; Steven S. Scherer, MD, PhD, The University of Pennsylvania, Philadelphia, PA, USA*

11.05-11.35 EDT  **FAP-What’s New?**
Merrill Benson, MD, Indiana University, Indianapolis, IN, USA
*Chairs: Mary Reilly, MD, UCL Institute of Neurology, London, UK; Michael Polydefkis, MD, MHS, Johns Hopkins Medicine, Baltimore, MD, USA*

11.35-12.05 EDT  **Mitofusins in Axonal Degeneration and Neuroprotection**
Robert Baloh, MD, PhD, Cedars-Sinai Medical Center, Los Angeles, CA, USA
*Chairs: Robert Burgess, PhD, The Jackson Laboratory, Bar Harbor, ME, USA; John Svaren, PhD, University of Wisconsin, Madison, WI, USA*

12.05-12.10 EDT  **Thank you, Farewell**
Michael Shy, MD, CMTR Chair, University of Iowa, Carver College of Medicine, Iowa City, IA, USA
IDNC Program
Tuesday 30 June 2020

10.00 – 12.10 EDT
INTERNATIONAL DIABETES NEUROPATHY CONSORTIUM (IDNC)

10.00-10.05 EDT Welcome & Introduction
Christopher Gibbons, MD, IDNC Chair, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

10.05-10.15 EDT IDNC Platform Presentations
Chairs: James Russell, MD, PhD, Professor of Neurology, University of Maryland, MD, USA; Vera Fridman, MD, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

10.05 EDT Increased Peptidergic Fiber Density and Macrophage Infiltration in The Skin in Painful Diabetic Polyneuropathy
Pall Karlsson, PhD, Danish Pain Research Center, Aarhus University, Aarhus, Denmark

10.20 EDT Neuronal LXR Regulates Neuregulin 1 Expression and Sciatic Nerve-Associated Cell Signaling in Western Diet-fed Rodents
Chaitanya Gavini, PhD, Loyola University Chicago, Maywood, IL, USA
10.35 EDT  Functional Characterization of Human Variants in the Pro-Degenerative Gene SARM1 and their Implication in Peripheral Neuropathies
Mirlinda Ademi, MD, University of Cambridge, Cambridge, United Kingdom

10.50 EDT  Protective Role of Schwann Cell p75NTR against Small Fiber Degeneration in Diabetic Neuropathy
Nádia Pereira Gonçalves, DVM, PhD, Department of Biomedicine, Aarhus University, Aarhus, Denmark

11.05 EDT  Fecal Transplantation Improves Peripheral Pain in Western Diet Murine Model
Raiza Bonomo, MS, Loyola University Chicago, Maywood, IL, USA

11.20 EDT  Cardiovascular Health Score and Chronic Axonal Polyneuropathy: A Population-based Cohort Study
Noor Taams, MD, Erasmus Medical Center, Rotterdam, The Netherlands

11.35 EDT  Microphysiological Modeling of Spinal Cord Synaptic Transmission Through 3-Dimensional Culture of Embryonic Rodent and Human-Derived Neural Tissue
Kevin Pollard, PhD, Tulane University, New Orleans, LA, USA

11.50 EDT  Novel Plasma Metabolomic Signatures Associated with Diabetic Neuropathy in a Cohort with Screen-Tested Type 2 Diabetes: ADDITION-Denmark
Amy Rumora, PhD, University of Michigan, Ann Arbor, MI, USA

12.05-12.10 EDT  Closing Remarks
James Russell, MD, PhD, Professor of Neurology, University of Maryland, MD, USA